In an article published last week in The Lancet, an international group of investigators examined whether ovarian cancer tumors’ expression of the progesterone receptor (PR) and estrogen receptor (ER) was associated with survival in various subtypes of ovarian cancer. To date, few biomarkers of ovarian cancer prognosis have been established.
The study, which included 2,933 women, found that PR an ER are prognostic biomarkers for endometriod and high-grade serous ovarian cancers. Clinical trials, which factor in both tumor subtype and biomarker status, are needed to establish whether hormone-receptor status predicts response to endocrine treatment, and whether it could guide personalized treatment for ovarian cancer.
Read the abstract here.
